| Name | IDH-305 |
|---|---|
| Synonyms |
2-Oxazolidinone, 4-[(1S)-1-fluoroethyl]-3-[2-[[(1S)-1-[4-methyl-2'-(trifluoromethyl)[3,4'-bipyridin]-6-yl]ethyl]amino]-4-pyrimidinyl]-, (4R)
IDH-305, 10 mM in DMSO IDH305 (IDH-305 IDH-305 ,S3574 (4R)-4-[(1S)-1-fluoroethyl]-3-(2-{[(1S)-1-[4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl]ethyl]amino}pyrimidin-4-yl)-1,3-oxazolidin-2-one Isocitrate Dehydrogenase (IDH),IDH-305,Inhibitor,IDH305,inhibit,IDH IDH305 IDH-305;IDH 305;IDH (R)-4-((S)-1-Fluoroethyl)-3-(2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one (4R)-4-[(1S)-1-Fluoroethyl]-3-[2-[[(1S)-1-[4-methyl-2'-(trifluoromethyl)[3,4'-bipyridin]-6-yl]ethyl]amino]-4-pyrimidinyl]-2-oxazolidinone |
| Description | IDH-305 is an inhibitor of isocitrate dehydrogenase (IDH). |
|---|---|
| Related Catalog | |
| Target |
IDH[1] |
| In Vitro | IDH-305 is an inhibitor of isocitrate dehydrogenase (IDH). Isocitrate dehydrogenase (IDH) is an essential enzyme for cellular respiration in the tricarboxylic acid (TCA) cycle. The IDH1 inhibitor IDH-305 has entered an ongoing phase 1 clinical trial (NCT02381886) for patients with IDH1-R132 mutant advanced hematologic or solid malignancies[1]. |
| References |
| Molecular Formula | C23H22F4N6O2 |
|---|---|
| Molecular Weight | 490.46 |
| Storage condition | 2-8℃ |